The world is evolving. Disinfection is no longer behind the scenes. You're handling more and more disinfection requests, but aren't getting more headcount.

The answer is automation. OhmniClean combines autonomous driving with serious UV-C germicidal power that tackles C.Diff, MRSA, and VRE in record time.

With product design optimized by working alongside real EVS teams, OhmniClean empowers you to meet the challenges of today and tomorrow.

Disinfect with Hospital-Grade Efficacy: Tested by a 3rd-party microbiology laboratory, OhmniClean has been proven to reduce pathogens with high efficacy and efficient exposure times. 

Audit UV-C dosage with dosimeters to ensure your hospital disinfection grade is kept to a high standard.

• Log6 reduction of E.Coli in < 3min
• Log4 reduction of C.Diff in < 3min
• Log6 reduction of MSRA in < 3min
• Log6 reduction of VRE in < 3min
• Log6 reduction in P. aeruginosa In < 3min

Unrivaled Performance & Flexibility: Handle more disinfection requests without more headcount. Handle large spaces and new areas that need disinfection.

Innovation: The product of choice for innovative EVS teams - future-proof & constantly improving.

Control Your Disinfection: Take the guesswork out of manual processes and let OhmniClean routinely disinfect your hospital environment. After every session, OhmniClean provides a disinfection report with in-room position tracking for managers to review the spaces that were covered. View auditable logs for disinfection sessions across all robots and staff in your organization.

Prepare your hospital for the future with OhmniClean.

OhmniLabs is a healthcare automation company focused on providing innovative robotic solutions. Since our founding in 2015, we’ve delivered thousands of robots that have improved the lives of people in more than 60 countries worldwide. OhmniLabs robots serve more than 700 large enterprise clients, including more than 80 hospitals. Our cutting-edge technology enhances patient care, streamlines workflow efficiency, and empowers healthcare professionals to focus on what matters most: delivering high-quality care with compassion and precision. Our USA-based manufacturing facility allows us to design, engineer, and build advanced robots for our customers with unrivaled usability and reliability. 

About ivWatch

IV insertion is the most common hospital procedure, yet up to 50% of them fail, often with severe consequences ranging from dosing errors, scarring, skin staining, nerve damage, amputation, and even death. Newport News, Virginia-based ivWatch is changing that.

Founded in 2010 and holding nearly 70 patents and counting, the company has developed a first-of-its-kind Class II medical device, cleared by the FDA and CE-marked, that uses visible and near-infrared light and a predictive algorithm to continuously monitor peripheral IVs to aid in the early detection of IV leakage events, also known as infiltration and extravasation. 

Applied to the skin at the IV site, ivWatch sensors perform over 18,000 checks per hour for signs of IV infiltration and extravasation, notifying healthcare workers of fluid leakage outside of the vein in real time to reduce severe adverse outcomes. 

In 2024, the company surpassed more than 35 clinical proof bodies. It was also named to Fast Company’s Most Innovative Companies list, the Inc. 2024 Best in Business list in the Health Products category, and was recognized by Modern Healthcare as one of its 2024 Best in Business. The company also reached the Top 3 in the 2024 Startup World Cup Grand Finale, from an initial group of over 8,000 global startups. To learn more, visit www.ivwatch.com.